text.skipToContent text.skipToNavigation
Pharma & Biotech

Basic NucleofectorTM Kit for Primary Mammalian Epithelial Cells

Catalog #: VVPI-1005
For transfection of mammalian epithelial cells lacking a cell type specific Optimized Protocol for the NucleofectorTM 2b Device
Size
Compare
SA

Product Overview

In addition to various cell type-specific kits for primary epithelial cells, we also provide a cell group-specific Basic NucleofectorTM Kit. This kit is suited to determine the optimal transfection conditions for any mammalian epithelial cell type that lacks a cell type specific Optimized Protocol for the NucleofectorTM 2b Device (or older generations I or II). In a first experiment a selection of different NucleofectorTM Programs is tested in combination with the Basic NucleofectorTM Solution for epithelial cells. The kit is available in different variants for either 10 or 25 or 4 x 25 reactions.

Benefits

  • Optimization can be performed within 1 experiment 
  • Detailed protocol guiding through the optimization procedure 
  • Optional result fine tuning with help of our Scientific Support Team 
  • Transfection efficiencies up to 83% - Viabilities up to 98%

Applications

  • Kit suited for epithelial cells from different mammalian species and various organs 
  • Already tested for renal proximal tubular epithelial cells (RPTEC) human prostate epithelial cells (hPrEc) and human small airway epithelial cells (SAEC)

Content & Storage

Content

4 x 2.25 mL NucleofectorTM Solution for Primary Mammalian Epithelial Cells
4 x 0.5 mL Supplement 1
4 x 30 µg pmaxGFPTM Vector (0.5 μg/μl in 10 mM Tris pH 8.0)
4 x 25 Aluminum cuvette (100 µL)
4 x 25 Single use pipettes

Instructions

Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

Interested in our Webinars?

Need a break from your daily routine? Grab a coffee and check out our free webinars. 

We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok